StartNCYT • LON
add
Novacyt SA
Seneste lukkekurs
69,40 GBX
Årsinterval
39,07 GBX - 137,00 GBX
Markedsværdi
55,90 mio. EUR
Gns. volumen
1,19 mio.
P/E-værdi
-
Udbytteprocent
-
Primær børs
EPA
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(GBP) | dec. 2023info | År til år-ændring |
---|---|---|
Indtægt | 4,12 mio. | 81,82 % |
Driftsudgifter | 12,52 mio. | 48,31 % |
Nettoindtægt | -9,97 mio. | -17,10 % |
Overskudsgrad | -242,04 | 35,59 % |
Earnings per share | — | — |
EBITDA | -7,10 mio. | -41,10 % |
Effektiv afgiftssats | 2,93 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(GBP) | dec. 2023info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 44,06 mio. | -49,34 % |
Samlede aktiver | 133,82 mio. | -5,03 % |
Samlede passiver | 46,57 mio. | 81,32 % |
Samlet egenkapital | 87,24 mio. | — |
Shares outstanding | 70,63 mio. | — |
Kurs/indre værdi | 0,56 | — |
Afkast af aktiver | -21,46 % | — |
Afkast af kapital | -28,44 % | — |
Pengestrøm
Nettoændring i likviditet
(GBP) | dec. 2023info | År til år-ændring |
---|---|---|
Nettoindtægt | -9,97 mio. | -17,10 % |
Pengestrøm fra drift | -9,65 mio. | -59,94 % |
Pengestrøm fra investering | -7,47 mio. | -3.853,70 % |
Pengestrøm fra finansiering | -1,72 mio. | -1.360,85 % |
Nettoændring i likviditet | -18,84 mio. | -197,44 % |
Fri pengestrøm | -3,81 mio. | -56,02 % |
Om
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Administrerende direktør
Grundlagt
2006
Website
Ansatte
237